Study S001617

Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls

ClinicalTrials.gov record

Registration

Registration: NCT03987308
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 115
Start: 2019-07-02
Primary completion: 2025-09
Lead sponsor: Beijing Hospital
Conditions: Type 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM
Interventions: DRUG:Beinaglutide; DRUG:Insulin aspart
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The proportion of subjects achieving HbA1c <7.0%, no weight increase (≤0 kg), and no hypoglycemia (blood glucose ≤3.9 mmol/L or severe hypoglycemia) after 8 weeks of treatment. [From baseline to the end of treatment at 8 week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.